Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 12:53 AM ET

Pharmaceuticals

Company Overview of Psyadon Pharmaceuticals, Inc.

Company Overview

Psyadon Pharmaceuticals, Inc. engages in the discovery and development of drugs for the treatment of diseases afflicting the central nervous system, primarily neurological and psychiatric diseases. Its Ecopipam product is an antagonist of the D1 dopamine receptor that blocks the actions of the neurotransmitter dopamine at the D1 receptor-family in the brain. Psyadon Pharmaceuticals, Inc. was formerly known as Ruxton Pharmaceuticals, Inc. and changed its name in November 2008. The company was founded in 2004 and is based in Germantown, Maryland.

20451 Seneca Meadows Parkway

Germantown, MD 20876

United States

Founded in 2004

Phone:

301-919-2020

Fax:

301-919-2020

Key Executives for Psyadon Pharmaceuticals, Inc.

Chief Executive Officer and President
Compensation as of Fiscal Year 2015.

Psyadon Pharmaceuticals, Inc. Key Developments

Psyadon Opens New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17

Psyadon Pharmaceuticals, Inc. announced the opening of the first four centers in a new Phase 2b clinical trial of ecopipam for the treatment of Tourette's Syndrome in children ages 7 to 17. Protocol PSY302 is a multicenter, double-blind, placebo-controlled, randomized two-way crossover study designed to assess the efficacy and safety of ecopipam in subjects with Tourette's Syndrome. Eligible subjects are instructed to take ecopipam (50 or 100 mg/day depending on body weight) or placebo before bedtime over an eight-week treatment period (comprised of two four-week treatment periods with either ecopipam or placebo). Due to the crossover design, all subjects will receive active medication at some time during the study. Efficacy will be measured using the Yale Global Tic Severity Scale, a well-validated, standard rating scale typically used when testing new pharmaceuticals.

Psyadon Pharmaceuticals, Inc. Announces Opening of Four Centers for Clinical Trial of Ecopipam

Psyadon Pharmaceuticals, Inc. announced the opening of the first four centers in a new Phase 2b clinical trial of ecopipam for the treatment of Tourette's Syndrome in children ages 7 to 17.

Similar Private Companies By Industry

Company Name Region
Lifesmart Nutrition Technologies Inc. United States
Sanochemia Corp. USA United States
Marnac, Inc. United States
Velocity Pharmaceutical Development, LLC United States
PharmPro Services United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Psyadon Pharmaceuticals, Inc., please visit www.psyadonrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.